PharmX Technologies (ASX:PHX) Current Deferred Revenue: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PharmX Technologies Current Deferred Revenue?

PharmX Technologies ASX:PHX Current Deferred Revenue is A$0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

PharmX Technologies's current deferred revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

PharmX Technologies Current Deferred Revenue Related Terms

PharmX Technologies Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Current Deferred Revenue Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.08 0.00 0.01 0.03

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.00 0.03 0.00
What does a Current Deferred Revenue of A$0.00 Mil mean?
PharmX Technologies (ASX:PHX) has a Current Deferred Revenue of A$0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Current Deferred Revenue too high?
PharmX Technologies' current Current Deferred Revenue is A$0.00 Mil.
How does PharmX Technologies' Current Deferred Revenue compare to VEEV and BTSG?
PharmX Technologies' Current Deferred Revenue of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Current Deferred Revenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.10 — trading 42.9% above its estimated fair value. The current Current Deferred Revenue is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Current Deferred Revenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.